Related Experiment Video
Updated: Nov 19, 2025
12:04
Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices
Published on: May 9, 2018
14.3K
Lung function and side effects of Aspirin desensitization: a real world study
Turpeinen Heikki1,2, Laulajainen-Hongisto Anu1,3, Lyly Annina1,3
1Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
European Clinical Respiratory Journal
|February 1, 2021
Summary
Acetylsalicylic acid desensitization (ATAD) for NSAID-exacerbated respiratory disease (N-ERD) showed limited impact on lung function but common side effects. Many patients discontinued treatment due to adverse events or lack of response.
Area of Science:
- Allergy and Immunology
- Respiratory Medicine
- Pharmacology
Background:
- NSAID-exacerbated respiratory disease (N-ERD) management relies on corticosteroids and acetylsalicylic acid desensitization (ATAD).
- Desensitization and ATAD can trigger respiratory symptom exacerbations and side effects, leading to treatment cessation.
Purpose of the Study:
- To evaluate the impact of ATAD on lung function and respiratory symptoms in N-ERD patients.
- To determine the incidence and nature of adverse events associated with ATAD.
Main Methods:
- Retrospective analysis of 67 N-ERD patients undergoing ASA desensitization (2006-2016).
- Data collected on adverse events, respiratory symptoms, lung function tests, and reasons for discontinuation.
Main Results:
- ATAD did not significantly alter lung function over up to 5 years of follow-up.
- Upper respiratory symptoms improved in 52% of patients, while lower respiratory symptoms improved in 10%.
- Adverse events, primarily dyspepsia and lower respiratory symptoms, occurred in 63% of patients, leading to high discontinuation rates.
Conclusions:
- ATAD demonstrates minimal impact on lower airway function in N-ERD.
- High rates of side effects and treatment discontinuation necessitate careful consideration of ATAD's risks and benefits.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
1.5K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.5K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.4K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.4K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
323
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
323
01:17Drugs Used in Lower Respiratory Disorders: Overview
824
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
824
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
667
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
667
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
3.2K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.2K